Abstract
Atrial natriuretic factor receptor guanylate cyclase (ANF-RGC), was the first discovered member of the mammalian membrane guanylate cyclase family. The hallmark feature of the family is that a single protein contains both the site for recognition of the regulatory signal and the ability to transduce it into the production of the second messenger, cyclic GMP. For over two decades, the family has been classified into two subfamilies, the hormone receptor subfamily with ANF-RGC being its paramount member, and the Ca2+ modulated subfamily, which includes the rod outer segment guanylate cyclases, ROS-GC1 and 2, and the olfactory neuroepithelial guanylate cyclase. ANF-RGC is the receptor and the signal transducer of the most hypotensive hormones, ANF– and B-type natriuretic peptide (BNP). After binding these hormones at the extracellular domain it, at its intracellular domain, signals activation of the C-terminal catalytic module and accelerates the production of cyclic GMP. Cyclic GMP then serves the second messenger role in biological responses of ANF and BNP such as natriuresis, diuresis, vasorelaxation, and anti-proliferation. Very recently another modus operandus for ANF-RGC was revealed. Its crux is that ANF-RGC activity is also regulated by Ca2+. The Ca2+ sensor neurocalcin d mediates this signaling mechanism. Strikingly, the Ca2+ and ANF signaling mechanisms employ separate structural motifs of ANF-RGC in modulating its core catalytic domain in accelerating the production of cyclic GMP. In this review the biochemistry and physiology of these mechanisms with emphasis on cardiovascular regulation will be discussed.
Keywords: atrial natriuretic factor, atrial natriuretic factor receptor guanylate cyclase, calcium, cyclic GMP, neurocalcin δ, signal transduction
INTRODUCTION
In the 1980s, the field of cellular signal transduction underwent total metamorphosis. Until then only two major paradigms of signal transduction, that of cyclic AMP and that of IP3 (inositol triphosphate) were known and were used to explain cellular signaling mechanisms and the second messenger concepts. Each of these two paradigms constituted an assemblage of three components – receptor, GTP binding protein, and the transducer catalyst – necessary for signal transduction. The astonishing discovery of a novel membrane protein that was simultaneously a receptor of a hormone and the transducer of its signal added a new dimension to our understanding of cellular signal transduction. The hormone was the newly described atrial natriuretic factor (ANF; de Bold, 1985) and the membrane protein was both its receptor and guanylate cyclase enzyme, termed therefore atrial natriuretic factor receptor guanylate cyclase (ANF-RGC; Kuno et al., 1986; Paul, 1986; Paul et al., 1987; Takayanagi et al., 1987; Meloche et al., 1988). Other terms to describe the protein are GC-A and NPR-A. ANF-RGC responded to ANF binding with accelerated synthesis of its second messenger cyclic GMP. The novelty of the system was 2-fold; first, a single protein, ANF-RGC, which contained both the ability to recognize the ANF hormonal signal and the activity to translate the hormonal information into the production of its second messenger, cyclic GMP was identified; and second, cyclic GMP was recognized as bona fide hormonal second messenger. Until then, the majority of laboratories forcefully denied the hormonal second messenger role of cyclic GMP (reviewed in Sharma, 2002, 2010).
The concept that ANF-RGC is indeed both hormone receptor and a catalyst was further supported by cloning studies (Chinkers et al., 1989; Lowe et al., 1989; Pandey and Singh, 1990; Duda et al., 1991; Marala et al., 1992). Homology cloning made possible finding other receptor membrane guanylate cyclases: C-type natriuretic peptide receptor guanylate cyclase, CNP-RGC (also known as GC-B; Chang et al., 1989; Schulz et al., 1989; Duda et al., 1993b) and heat-stable enterotoxin (also guanylin and uroguanylin) receptor guanylate cyclase, STa-RGC (GC-C; Schulz et al., 1990; de Sauvage et al., 1991; Singh et al., 1991; Hamra et al., 1993; Khare et al., 1994). Identification of these three structurally and functionally related membrane guanylate cyclases that were receptors for hormonally active peptides resulted in a notion that all membrane guanylate cyclases, even those still to be discovered, were receptors for specific extracellular ligands.
The notion was short-lived, however. The next four, in chronological order, identified membrane guanylate cyclases: the rod outer segment guanylate cyclases, ROS-GC1 (also known as RetGC1 or GC-E; Koch, 1991; Shyjan et al., 1992; Goraczniak et al., 1994) and ROS-GC2 (RetGC2 or GC-F; Lowe et al., 1995; Yang et al., 1995; Goraczniak et al., 1998), the olfactory neuroepithelium guanylate cyclase, ONE-GC (also termed as GC-D) (Fulle et al., 1995; Duda et al., 2001a) and GC-G (Schulz et al., 1998), did not respond with increased activity to any extracellular ligand. They were therefore branded as “orphan receptors” (Fulle et al., 1995; Yang et al., 1995; Wedel and Garbers, 1997; Schulz et al., 1998).
ROS-GC1 and ROS-GC2 were not orphan RGC, however. Biochemical and physiological findings began to reveal that regulation of their catalytic activities is specific to their physiological function which is to return the illuminated photoreceptors to the dark, resting state. The illumination leads to activation of cyclic GMP phosphodiesterase, depletion of cyclic GMP, closure of the cyclic GMP gated (CNG) channels, and lowering the free Ca2+ concentration (reviewed in Pugh et al., 1997; Koch et al., 2010). The ROS-GCs’ task is to restore the dark-level of cyclic GMP allowing opening of the CNG channels and increase of Ca2+ influx. Ca2+ concentration, thus, determines the activity of ROS-GCs but it occurs in an indirect way. Guanylate cyclase activating proteins (GCAPs) sense the post-illumination fall in Ca2+ and stimulate ROS-GCs to resynthesize cyclic GMP at a faster rate (reviewed in Detwiler, 2000; Koch et al., 2010). In this cyclic GMP-Ca2+ feedback mechanism, ROS-GCs do not respond to an extracellular ligand but to their intracellular Ca2+ sensing ligands, the GCAPs (Palczewski et al., 1994; Dizhoor et al., 1995; Duda et al., 1996b).
Soon thereafter the evidence began to emerge, primarily from our laboratory, that GCAPs are not the only Ca2+ sensing modulators of ROS-GC activity. While increasing Ca2+ concentrations inhibit ROS-GCs activity through GCAPs, two other Ca2+ sensors, S100B, and neurocalcin δ (NCδ) stimulate ROS-GC1 in a Ca2+-dependent fashion (Pozdnyakov et al., 1995; Duda et al., 1996a; Margulis et al., 1996; Kumar et al., 1999). The Ca2+-dependent S100B-mediated activation of ROS-GC operates in cones including their outer segments and pedicles (Wen et al., 2012). Its role in photo- and visual transductions remains to be established, but existing data indicate its involvement in transmission of the visual signal from cone ON-bipolar cells (Wen et al., 2012). Ca2+ signaling of ROS-GC activity mediated by NCδ is operative in retinal ganglion cells (Krishnan et al., 2004) but its linkage with the visual transduction is not clear yet.
Similar, but with additional twists, regulation of ONE-GC occurs in a subset of olfactory sensory neurons (Fulle et al., 1995; Duda et al., 2001a; Pertzev et al., 2010). The cyclase was initially classified as a member of the Ca2+ modulated subfamily (Duda et al., 2001a). Its activity is modulated in a Ca2+-dependent fashion by NCδ (Duda et al., 2001a, 2004) and by GCAP1 (Duda et al., 2006, 2012a; Pertzev et al., 2010). Remarkably, the Ca2+-GCAP1 pattern of ONE-GC modulation is opposite to that of ROS-GC modulation. Sensing increasing concentrations of Ca2+ GCAP1 stimulates ONE-GC while it inhibits ROS-GC (Duda et al., 2006, 2012a).
After the Ca2+-dependent modulation of ONE-GC activity was demonstrated, an extracellular ligand of the cyclase was found. The ligand was the odorant uroguanylin (Leinders-Zufall et al., 2007; Duda and Sharma, 2008; reviewed in Sharma and Duda, 2010; Zufall and Munger, 2010). Hence, ONE-GC responds to both extracellular (uroguanylin) and intracellular Ca2+ signals. At this point a new, two-step “cross-talk” odorant transduction model was proposed (Duda and Sharma, 2009). In “step 1,” the odorant uroguanylin interacts with the receptor domain of ONE-GC, causing its minimal activation. The cyclic GMP generated in response to uroguanylin signal opens a few of the CNG3 channels leading to some increase in [Ca2+]i in the odorant receptor cell. In “step 2,” the membrane bound NCδ and GCAP1 sense the increase in [Ca2+]i and in their Ca2+-bound states fully activate ONE-GC triggering maximal influx of Ca2+and depolarization of the olfactory receptor cell membrane.
The odorant receptor ONE-GC linkage with the intracellular free Ca2+ signals brought forth a question whether this cyclase is a unique case of dually regulated membrane guanylate cyclase. Latest studies from our laboratory demonstrate that it is not. The nascent member of the hormone receptor subfamily, the ANF-RGC, is also responsive to Ca2+ (Duda et al., 2012a,b) and NCδ is the sensor protein which communicates the Ca2+ signal to ANF-RGC and in the Ca2+-bound state, activates ANF-RGC activity. The two modes of ANF-RGC activation, hormonal and Ca2+-dependent, engage their specific and independent pathways of transmitting the stimulatory signals to the catalytic domain. The end-product, however, is common, the second messenger cyclic GMP. Because of the individual signaling mechanisms involved in Ca2+ and hormonal signaling their net effects are multiplicative. Hence, in terms of the original sub-classification, the present day knowledge is that at least two cyclases, ANF-RGC and ONE-GC, are hybrids sensing both hormonal and Ca2+ signals.
The last cloned membrane guanylate cyclase was GC-G. Until today, the information of its function is very scarce. It was suggested that the mouse form of GC-G is selectively expressed in the sperm and may be involved in the process of capacitation (Kuhn et al., 2004). Other reports suggest that the cyclase is expressed in Grueneberg ganglion olfactory subsystem where it is responding to CO2 (Chao et al., 2010) or to cool ambient temperature indicating its role in thermo-sensation (Mamasuew et al., 2008).
The following discussion is exclusively devoted to the ANF-RGC. It was the first template model, which established that cyclic GMP is a bona fide hormonal second messenger. The ongoing studies define the second ANF-RGC transduction model, Ca2+-modulated signaling. It makes ANF-RGC a bimodal switch, hormonal and Ca2+. An additional significant part of the review is coverage of the manner in which these two models have now begun to explain the biochemical principles of cardiovascular, renal and endocrine homeostasis with special emphasis on blood pressure regulation.
HORMONAL SIGNALING OF ANF-RGC ACTIVATION
BINDING OF LIGAND-HORMONE ANF
Although intuitively expected, the first experimental evidence that the ANF binding site in ANF-RGC is located within the extracellular domain came first from the site-directed and deletion mutagenesis studies. A mutant ANF-RGC was cloned from rat adrenal cDNA library (Duda et al., 1991) and termed GCα. Its sequence differed from ANF-RGC by two amino acid substitutions Q338 → H and L364 → P which resulted from single nucleotide mutations, CAG → CAC and CTG → CCG, respectively. Expressed in heterologous system of COS cells, GCα was properly located in the plasma membrane and exhibited basal guanylate cyclase activity; it however, neither bound nor responded to ANF or other natriuretic peptides (Duda et al., 1991). These results demonstrated that the two amino acid substitutions exclusively abolished binding of ANF and therefore ANF signaling of the cyclase activity. Restoration by site-directed mutagenesis, glutamine at position 338 and leucine at position 364, reinstated ANF binding and ANF-dependent stimulation of the cyclase.
The site of ANF binding was further systematically analyzed (McNicoll et al., 1992, 1996; He et al., 1995; Misono, 2002). By cross-linking and proteinase digestion it was determined that the amino terminus of ANF is in contact with the region M173-F188 of ANF-RGC, and the C-terminus, with D191-R198 region. The fact that the identified contact sites were very close to each other was interpreted that the N- and C- termini of ANF interface distinct subunits of ANF-RGC homodimer. Importantly, it also implied that one ANF-RGC dimer binds one molecule of ANF.
Details of ANF binding to the ANF-RGC extracellular domain were unraveled by analyses of the extracellular domain of ANF-RGC co-crystallized with ANF (Ogawa et al., 2003, 2004). These analyses revealed that (1) the extracellular domain of ANF-RGC exists as a dimer in the head-to-head configuration; (2) one ANF-RGC dimer binds one molecule of ANF (2:1 complex); (3) the binding site in one monomer differs from that in the other - one monomer binds the N-terminal part of ANF and the other binds C-terminal part; (4) there is no preference in ANF binding to a specific monomer of the extracellular domain; bound ANF occurs in two alternate orientations of equal occurrence; (5) the membrane-distal portion of the extracellular domain contains chloride ion necessary for ANF binding.
TRANSMEMBRANE MIGRATION OF THE ANF BINDING SIGNAL
With the exception of enterotoxin RGC, all membrane guanylate cyclases contain a hinge region juxtaposed to the N-terminal side of the transmembrane domain. This region contains two conserved cysteine residues separated from each other by 6–8 residues. In ANF-RGC these residues are Cys423 and Cys432 and were indicated as a critical structural motif in ANF signaling (Huo et al., 1999; Labrecque et al., 1999; Miyagi and Misono, 2000). There was however no consensus on the mechanism of its operation. Based on results with intact cells transfected with ANF-RGC cDNA it was proposed that the cysteines are involved in dimerization through the formation of an inter-chain S-S bridge (Huo et al., 1999; Labrecque et al., 2001) or, that they form an intra-chain disulfide bridge (Huo et al., 1999; Miyagi and Misono, 2000). Analyses of guanylate cyclase activity in isolated membranes of COS cell expressing C423S, C432S, and C423S, C432S mutants (Duda and Sharma, 2005) allowed to conclude that both C423 and C432 residues independently and equally control the catalytic activity of ANF-RGC and that activation of ANF-RGC does not involve interchain-disulfide bond formation. In the basal state, the disulfide motif keeps the ANF-RGC in its repressed catalytic state and ANF/ATP signaling brings it to the fully active state (Duda and Sharma, 2005).
A model of hormone-induced rotation has been proposed to explain how the extracellular signal is transmitted through the hinge region to the intracellular domain of ANF-RGC (Ogawa et al., 2004; Misono et al., 2005). Binding of ANF causes a twist motion of both ANF-RGC monomers centered on a support point close to the bound ANF. This twist motion translocates the juxtamembrane domains of both monomers with only minimal change in the distance between them. This movement constitutes a signal, which is transmitted through the transmembrane domain. Rotation of the transmembrane domain by 40 degrees occurs in response to ANF binding (Parat et al., 2010).
PASSAGE OF THE ANF SIGNAL THROUGH THE INTRACELLULAR DOMAIN
ANF signaling requires ATP
Early studies, before the biochemical characterization of ANF-RGC, demonstrated that activation by ANF is significantly amplified by ATP in the guanylate cyclase activation (Kurose et al., 1987; Cole et al., 1989; Chang et al., 1990; Larose et al., 1991; reviewed in Sharma, 2002; Duda et al., 2005). Subsequently, it was demonstrated that ATP is obligatory for ANF-dependent activation of ANF-RGC (Chinkers et al., 1991; Marala et al., 1991; Goraczniak et al., 1992; Wong et al., 1995; reviewed in Duda et al., 2005). Because the ATP effect was mimicked by its non-hydrolyzable analogs, ATPγS and AMP-PNP, it was suggested that ATP acts as an allosteric regulator (Chinkers et al., 1991; Marala et al., 1991; Goraczniak et al., 1992; Wong et al., 1995; reviewed in Duda et al., 2005). Shortly thereafter it was shown that ATP is also obligatory for the CNP-dependent stimulation of CNP-RGC (Duda et al., 1993a,b). Thus, it appears that the requirement of ATP is a common attribute of natriuretic peptide RGC signaling.
Studies with ANF-RGC deletion mutants revealed that the ATP regulated region resides in the intracellular portion of ANF-RGC between the transmembrane and the C-terminal catalytic domain (Chinkers and Garbers, 1989; Goraczniak et al., 1992). This region was named the kinase homology (or kinase-like domain; KHD or K-LD) because of its sequence similarity with the corresponding domains of tyrosine kinases (Chinkers et al., 1989; Chinkers and Garbers, 1989; Duda et al., 1991). A model for the ATP function was proposed that “binding of ANP to the extracellular domain of its receptor initiates a conformational change in the protein K-LD, resulting in de-repression of guanylate cyclase activity” (Chinkers and Garbers, 1989). The central idea behind the model was that KHD in native ANF-RGC suppresses the catalytic module activity; ANF functions by relieving this suppression. Study from our group using two KHD deletion mutants, Δ506–677 and Δ555–762, negated this model and proposed an alternative one where ATP via ATP regulated module (ARM) potentiates the hormonal signal “(1) the signal is caused by the binding of the hormone to the receptor site; (2) there is a transmembrane migration of the signal; (3) the signal is potentiated by ATP at ARM; and (4) the amplified signal is finally transduced at the catalytic site” (Goraczniak et al., 1992).
ATP allosteric effect and the ARM domain
Within the KHD ANF-RGC contains a sequence, G503-X-G505-X-X-X-G509 (Goraczniak et al., 1992) which is a modified form of the protein kinases’ nucleotide-binding consensus sequence G-X-G-X-X-G necessary for kinase activity (Wierenga and Hol, 1983; Hanks et al., 1988; Bratová et al., 2005). This motif was probed for its significance in ATP function in ANF signaling. Through analyses of a series of deletion and point mutants it was determined that the G503-X-G505-X-X-X-G509 motif is critical for the ATP function (Goraczniak et al., 1992; Duda et al., 1993a; Duda and Sharma, 1995; reviewed in Sharma, 2002; Duda et al., 2005). Although it is not involved in ATP binding it maintains the steric arrangements to fit the ATP molecule. For this reason, the motif has been named ARM (Goraczniak et al., 1992) and the KHD, where the ARM resides, was termed the ARM domain (Duda et al., 2001b; Sharma et al., 2001). To get an insight into the mechanism of ATP function, the structure of the ARM domain was simulated through computer-assisted homology based modeling (Duda et al., 2001b; Sharma et al., 2001; PDB ID 1T53). The basic structural features of the model have been experimentally validated through point mutation/expression studies (Duda et al., 2001b; Sharma et al., 2001; reviewed in Sharma, 2002; Duda et al., 2005).
Spatial determinants of the ARM domain. The domain comprises amino acid residues 496–771, which are arranged into two lobes: the smaller, N-terminal (91 aa residues: 496–586), and the larger, C-terminal (185 aa residues: 587–771; Duda et al., 2001b). Four antiparallel β strands and one α helix form the smaller lobe; the larger lobe is predominantly helical, composed of eight α-helices and two β strands (Duda et al., 2001b; Sharma et al., 2001). The ARM motif, G503-X-G505-X-X-X-G509, is located within the smaller lobe.
The ATP-binding pocket. In order to identify the ARM domain residues potentially involved in ATP binding the model of this domain in its ATP-bound form was analyzed (Duda et al., 2005). A radius of 4 Å from the ATP molecule was chosen as the limiting distance for the electrostatic, hydrogen or van der Waals’ interactions. Two sets of residues were identified (Figure 4 in reference Duda et al., 2005): (1) those forming the floor of the ATP binding pocket; (2) those surrounding ATP molecule. The residues in the first set are: G503, R504, G505, S506, N507, Y508, and G509. These residues have no direct chemical interaction with ATP; they, however, provide necessary space to accommodate the ATP molecule. The residues in the second set surround the individual components of ATP, the adenine ring, the ribose ring and the triphosphate moiety. The adenine ring is surrounded by L511, T513, T514, E515, Q517, A533, T580, E581, C583, V635, and T645 and L511, T513, and C583 are within a distance shorter than 3 Å.
G503, L511, T513, T514, G580, S587, D590surround the ribose ring with L511 and T514 located within 2.5 Å radius from the ribose. The phosphate groups are surrounded by R504, G505, L511, K535, N633, D646, and K535 is the nearest residue (2.6 Å) forming a hydrogen bond with the phosphate and has been shown to be critical for ATP regulation of ANF-dependent ANF-RGC activity; D646 interacts with the triphosphate group of ATP through the formation of a coordinate bond with the metal ion Mg2+.
Interaction of ATP with the ARM domain. Kinetics of ATP binding to the ARM domain was determined through SPR spectroscopy (Burczynska et al., 2007). AMP-PNP, the non-hydrolyzable analog of ATP was used for the binding studies. Half-maximal binding (EC50) occurred when the concentration of AMP-PNP was ~0.2 mM and the calculated KD value was 0.21 mM. Similar results (EC50 value of 0.15 mM and KD of 0.13 mM) were obtained when 8-azido-ATP was used.
The model-predicted ATP binding pocket (vide supra) was authenticated experimentally by cross-linking of the purified isolated ARM domain protein with 8-azido-ATP, trypsin digestion of the cross-linked product and sequencing of the resulting peptides (Burczynska et al., 2007). Three peptides were found to be photoaffinity modified. The longest modified peptide was identified as G614MLFLHNG-AICSHGNLKSSNCVVDGR639and the shortest as S631SNC634V635VDGR. In all three peptides Cys634was modified indicating that this residue was the closest to the azido group. The G614–R639 fragment contains six ATP-binding pocket-predicted residues (Duda et al., 2005): S625, K630, S631, S632, N633, and V635; and the shortest S631–R639 fragment contains three residues: S631, N633, and V635(Duda et al., 2005). The refined ARM model (Duda et al., 2005) predicts that V635 is within a 4 Å radius from the adenine ring; cross-linking of the neighboring residue to C634 validates that these residues are indeed the closest to the C-8 of the adenine ring.
ATP binding dependent changes in the ARM domain. If ATP binding to the ARM domain were to serve signaling purposes, it should induce structural changes that ultimately would signal activation of the catalytic domain. Comparative analyses of the ARM domain models in the apo and ATP-bound states identified such changes. They involve rotations of the β strands within the smaller lobe as well as movements of the β strands and α helices in the larger lobe (Duda et al., 2001b; Sharma et al., 2001; reviewed in Duda et al., 2005). Consequences of two such changes appear to be of particular importance: first, of the β1, β2 strands in the smaller lobe, and the second, of the EF and F helices in the larger lobe.
The β1 and β2 strands and the loop connecting them encompasses the G503-X-G505-X-X-X-G509 motif (Duda et al., 2001b; Sharma et al., 2001; reviewed in Duda et al., 2005), which is meshed in and flanked by six phosphorylation sites, S497, T500, S502, S506, S510, T513 (Potter and Hunter, 1998a, 1999a). The present consensus is that “phosphorylation of KHD is absolutely required for hormone-dependent activation of NPR-A” (Potter and Hunter, 1998a,b, 1999b). In this concept, hypothetical protein kinase and protein phosphatase co-exist with ANF-RGC (Foster and Garbers, 1998). Until now, however, neither the kinase nor the phosphatase has been identified.
Comparison of the ATP-free and ATP-bound ARM domain models allows explaining how ATP binding makes it possible for the serine and threonine residues to undergo phosphorylation. After ATP binds to the ARM domain, the β1, β2 strands, and the loop between them shift by ~3–4 Å and rotate by ~15° (Duda et al., 2001b; Sharma et al., 2001; reviewed in Duda et al., 2005). This movement triggers reorientation of the serine and threonine residues (Figure 1, red colored residues) causing the side chains and the OH groups of T500, S502, S506, and T513 becoming directed toward the protein surface (Figure 1, compare the positions of the cyan- and red-colored OH groups). The change in the positions of the side chains is most drastic for the S502 and S506 residues. Although upon ATP binding there is no toward the surface reorientation of the S497 and S510 OH groups, the entire residues are shifted toward the surface (Figure 1). This structural rearrangement permits the hypothetical protein kinase to access the side chains of the residues and transfer the phosphate group (Duda et al., 2011).
Another important result of ATP binding on the dynamics within the ARM domain is the translocation within the larger lobe of two helices, EF and F. Their movement was characterized by analyzing the ATP-dependent changes in the fluorescence intensity and wavelength of two tryptophan residues W601 and W669 (Duda et al., 2009). Both residues reside in the larger lobe of the ARM domain, outside the ATP-binding pocket. The W601 residue is a part of the helix E structure (Duda et al., 2001b, 2005), its side-chain is oriented toward the protein surface, and it is flanked by several hydrophobic residues, F640, L607, S606, and S596 (Figure 2A). These structural features define the fluorescence λmax of W601 at 332 nm. W669 residue is located at the end of a loop connecting β8 strand and EF helix (Duda et al., 2009); it is a part of a conserved hydrophobic motif, 669WTAPELL675. The side chain of W669 is flanked by the polar residues: E699, S631, K667, K630, and L696 (Figure 2B). This environment causes red shifts in the fluorescence λmax of W669 to 345 nm.
Superimposition of the ATP-free and the ATP-bound forms indicates that ATP binding induces contraction of the entire ARM domain and affects the orientation and environment of W669. The contraction results in shortening of the distance between W669 and the ATP binding pocket (Figure 2C). ATP binding also causes reorientation of the W669 side chain. It turns and becomes more shielded by the surrounding amino acids. Turning of the W669 side chain pushes the remainder of the motif, 670TAPELL675, to the surface resulting in its exposure. In general, the movement of a hydrophobic motif toward the surface of the protein indicates its readiness for interaction. For the 669WTAPELL675 motif it was proposed that it interacts with subsequent transduction motif, possibly within the catalytic domain, propagates the ANF/ATP binding signal and activates the catalytic domain (Duda et al., 2009).
Based on the studies narrated above a model for ANF/ATP signaling of ANF-RGC activity was proposed: The ANF signal originates by the binding of one molecule of ANF to the extracellular dimer domain of ANF-RGC (Ogawa et al., 2004, 2009). The binding modifies the juxtamembrane region where the disulfide 423Cys-Cys432 structural motif is a key element in this modification (Ogawa et al., 2004, 2009; Duda and Sharma, 2005). The signal twists the transmembrane domain (Parat et al., 2010), induces a structural change in the ARM domain, and prepares it for the ATP activation. ARM domain binds ATP to its pocket what leads to a cascade of temporal and spatial changes (Duda et al., 2001b; Sharma et al., 2001; reviewed in Duda et al., 2005). They result in (1) exposure of the hydrophobic 669WTAPELL675 motif which directly (or indirectly) interacts with the catalytic domain causing its partial activation; and (2) exposure and phosphorylation of six serine, threonine residues and full activation of ANF-RGC. Concomitantly, phosphorylation converts ATP binding site from the high to low affinity, ATP dissociates and ANF-RGC returns to its ground state (Duda et al., 2011).
CATALYTIC DOMAIN
When more then 20 years ago an ANF RGC was purified to homogeneity and shown to contain the ANF binding and cyclic GMP forming activities on the same protein chain, the authors proposed a topological model for the transmembrane receptor enzyme in which the receptor part was extracellular and the cyclase catalytic domain was intracellular (Sharma et al., 1988a,b). The cloning studies confirmed this prediction. Alignment of the deduced amino acid sequences of the cloned guanylate cyclases indicated that the catalytic domain is located at the C-terminus of ANF-RGC and comprises 239 amino acid residues (Chinkers et al., 1989; Duda et al., 1991). This prediction was tested experimentally (Thorpe and Morkin, 1990; Thorpe et al., 1996). The carboxy terminal 293 amino acids fragment of ANF-RGC was expressed as a soluble protein and shown to exhibit guanylate cyclase activity. These results were in agreement with studies that determined through radiation inactivation experiments that the ANF-RGC fragment containing cyclase activity has a molecular weight of 32 ± 8 kDa (Tremblay et al., 1991). Further studies identified several residues within this region that appeared to be critical for the guanylate cyclase activity: L817 (Miao et al., 1995), D877, K887, D893, G900, H909, R940, and H944 (Thompson and Garbers, 1995). Their individual mutations to Ala resulted in ANF-RGC mutants without detectable guanylate cyclase activity. In contrast to these residues, mutation of E974 to Ala resulted in a hyperactive ANF-RGC mutant (Wedel et al., 1997). Based on these results it was concluded that the indicated residues are located within or close to the catalytic center or are critical for the proper folding of the catalytic center.
In the absence of a crystal structure of any membrane guanylate cyclase catalytic domain a model of the catalytic center of retGC-1, a mammalian membrane guanylate cyclase expressed in the retina, also known as ROS-GC1 was proposed (Liu et al., 1997). The model was built based on homology with the catalytic center of the adenylate cyclase. The modeling studies allowed identification of the critical residues constituting the catalytic core. Because the catalytic domains of all membrane guanylate cyclases are highly conserved (>95% of sequence identity), by homology substitution, the critical residues of the ANF-RGC catalytic center have been identified and they are described below.
The catalytic center is homodimeric. There are two GTP binding sites. Each GTP molecule interacts with both monomers. In the following description of the ANF-RGC catalytic center the monomers are labeled “A” and “B” and the location of each residue within a monomer A or B is indicated. Numbering of amino acids is according to the mature protein (Duda et al., 1991). R959(B) and C961(B) interact with guanine’s O6; second NH2 group of R959(B) interacts with guanine’s N1; the carboxy group of E889(B) interacts with R959(B) and through it with N1; G964(B) interacts with N7; T854(A), D893(A) and N968(B) form hydrogen bonds with ribose’s OH (3′) group; R972(B binds α phosphate group; R940(A) binds β phosphate group; E974(A) through Mg2+ interacts with β phosphate group; and S971(A) binds γ phosphate group. Specificity toward GTP is determined by E889 and C961 of ANF-RGC. This conclusion is drawn based on studies showing that in ROS-GC1 mutation of the corresponding E to K and C to D converts guanylate cyclase activity into adenylate cyclase activity (Tucker et al., 1998).
Mechanism of ANF-RGC activation – the role of the 669WTAPELL675 motif
An important feature of the model of ANF/ATP-dependent activation of ANF-RGC is the relay function of the 669WTAPELL675 motif. It switches between the ATP-bound ARM domain and activates the catalytic domain. It was proposed that this motif interacts with and signals the antiparallel homo-dimer of the catalytic domain to undergo conformational changes and form a functional catalytic center (Duda et al., 2009). The exact site within the catalytic domain which is targeted by the 669WTAPELL675 motif remains to be determined. Preliminary scanning experiments, however, suggest that the site may be located close to the E889, a residue critical for cyclase specificity toward GTP (Tucker et al., 1998).
If the elements of the model are correct and the 669WTAPELL675 motif is a switch, its deletion from the ANF-RGC should lead to a protein which binds ANF and ATP but is not able to respond to them with increased synthesis of cyclic GMP. This assumption was tested experimentally. An ANF-RGC mutant was created in which the 669WTAPELL675 motif was deleted by mutagenesis. Wild type ANF-RGC and the mutant were expressed individually in COS cells and their membranes were analyzed (1) by Western blot to determine the proteins’ levels of expression; (2) for basal guanylate cyclase activity; (3) for ANF binding; and (4) for KM for the substrate GTP. The results demonstrated that (1) the wild type ANF-RGC and the 669WTAPELL675 deletion mutant were expressed to the same level as determined by Western blot; (2) the basal cyclase activity of the mutant, 20 pmol cGMP min-1 (mg protein)-1, was virtually identical to that of the wild type ANF-RGC, 21 pmol cGMP min-1 (mg protein) -1; (3) their receptor activities were equal with the respective specific binding values of 9.7 ± 0.6 and 10.1 ± 0.9 pmol [125I]ANF/mg protein and (4) the KM values for the substrate GTP, 614 μM for the wild type and 608 μM for the mutant protein were identical. Thus, the basal integrity of the protein remained intact despite the deletion (Duda et al., 2009).
When the mutant was exposed to increasing concentrations of ANF and ATP its cyclase activity remained practically unchanged whereas under identical conditions wild type ANF-RGC was stimulated over 6-fold (Duda et al., 2009, 2013) demonstrating that in line with the original expectations the catalytic domain does not increase cyclic GMP synthesis in the presence of ANF/ATP. This type of outcome could only be observed if the mutant protein did not bind ANF and/or ATP or the catalytic domain lost its cyclase ability. Both of these possibilities were put to rest as the mutant and the wild type cyclase did not differ in ANF and ATP binding nor in enzymatic activity (vide supra and ref. Duda et al., 2009). Therefore the only explanation for the unchanged level of cyclic GMP synthesis is that the 669WTAPELL675 deletion mutant is not able to respond to ANF and ATP. This leads to just one logical conclusion that in the absence of the 669WTAPELL675 motif the ANF/ATP binding information is not transmitted to the catalytic domain. Thus, the 669WTAPELL675 motif is the critical transmitter of the ATP-potentiated ANF signal to the catalytic domain where it is translated into generation of cyclic GMP.
Ca2+ SIGNALING OF ANF-RGC ACTIVITY
NEURONAL CALCIUM SENSOR NEUROCALCIN δ
Neurocalcin δ belongs to a distinct subfamily of neuronal calcium sensor proteins (NCS) together with visinin-like proteins (VILIPs) and hippocalcin. They all are acylated at the N-terminus by myristic acid and undergo a classical calcium-myristoyl switch (Ladant, 1995), e.g., they bury the myristoyl group in a hydrophobic pocket in Ca2+-free form and expose it in Ca2+-bound form, as first observed and described for recoverin (Zozulya and Stryer, 1992). Exposure of myristoyl group enables the protein association with the cell membrane. However, once it binds, in a Ca2+-dependent fashion, to the membrane phospholipids, even after removing Ca2+ by the addition of EGTA part of it remains membrane bound (Krishnan et al., 2004). Although NCδ is primarily expressed in neuronal tissues, its expression in the periphery is also observed.
Functionally, NCδ has been linked to receptor endocytosis through interaction with α- and β-clathrin and β-adaptin (Ivings et al., 2002), trafficking and membrane delivery of glutamate receptors of the kainate type (Coussen and Mulle, 2006), and due to its Ca2+-dependent affinity for S100B protein and tubulin β-chain (Okazaki et al., 1995), with microtubule assembly (Iino et al., 1995). In the sensory and sensory-linked neurons, the presence of NCδ has been found in the inner plexiform layer of the retina, e.g., in the amacrine and ganglion cells (Krishnan et al., 2004), olfactory sensory neurons (Duda et al., 2001a, 2004) and recently, it has been identified in type II cells of mouse circumvallate taste papillae, indicating its possible role in gustatory transduction (Rebello et al., 2011).
A relatively newly identified function of NCδ is its Ca2+-dependent modulation of the activities of membrane guanylate cyclases ROS-GC1 in the retina and ONE-GC, in the olfactory neuroepithelium (Duda et al., 2001b, 2004; Krishnan et al., 2004). In these tissues NCδ co-localizes with its respective target cyclases. The exact physiological significance of the ROS-GC1- NCδ signaling system in the retinal neurons is not known yet. It can be, however, safely stated that the pathway is not present in the rod and cone outer segments, thus is not linked with the phototransduction machinery. The system has been localized to the lower strata of the inner plexiform layer and to a subpopulation of ganglion cells (Krishnan et al., 2004).
In the olfactory neuroepithelium NCδ serves as a Ca2+ sensor component of the two-step odorant uroguanylin signaling machinery. This signaling mechanism was proposed to be initiated by uroguanylin interaction with the extracellular receptor domain of ONE-GC (Leinders-Zufall et al., 2007; Duda and Sharma, 2008; reviewed in Zufall and Munger, 2010; Sharma and Duda, 2010). This interaction leads to partial activation of ONE-GC, generation of small amount of cyclic GMP, partial opening of cyclic GMP-gated channel and influx of Ca2+ into the olfactory receptor neuron. In the next step, Ca2+ binds to NCδ which, then fully activates ONE-GC (Duda and Sharma, 2009).
FREE CA2+ SIGNALS ANF-RGC ACTIVATION
In the course of mapping the NCδ targeted site on ROS-GC1 to which it binds and transmits the Ca2+ signal to the catalytic domain for signal translation into the generation of cyclic GMP, our group made a remarkable observation that NCδ binds directly to the catalytic domain and, thereby, activates ROS-GC1 (Venkataraman et al., 2008). Protein database comparison shows sequence conservation of the catalytic domain in the membrane guanylate cyclase family hinting at a possibility that other membrane guanylate cyclases might be activated by Ca2+ via NCδ as well. To test this possibility, ANF-RGC membrane guanylate cyclase, for which the only established signal transduction mechanism was through ANF/ATP (vide supra), was chosen. And indeed, in a recombinant system, myristoylated NCδ stimulated ANF-RGC activity in a dose- and Ca2+-dependent manner; 0.5 μM Ca2+ and 0.5 μM NCδ triggered half-maximal activation of ANF-RGC (Duda et al., 2012a,b). These results for the first time demonstrated that ANF-RGC activity is dually regulated, by peptide hormones ANF and BNP, and by Ca2+, thus, at least in vitro the cyclase was deemed a bimodal signal transducer.
Myristoylated dimeric form of neurocalcin δ is the transmitter of the Ca2+ signal
Since NCδ belongs to the family of NCS and myristoylation at N-terminus is a characteristic feature of a majority, but not all, of these proteins important for their cellular function, it was necessary to check whether myristoylation was required for NCδ to transmit the Ca2+ signal for ANF-RGC activation. Reconstitution experiments of ANF-RGC with both myristoylated and non-myristoylated NCδ showed that only the myristoylated NCδ stimulated the cyclase activity whereas the non-myristoylated form was ineffectual (Duda et al., 2012b). Importantly, both forms exhibited comparable affinity for ANF-RGC. In addition to activating ANF-RGC myristoylated NCδ also lowered the cyclase’s KM for substrate GTP and increased its catalytic efficiency, kcat, from 6.5 ± 0.3 to 41.4 ± 0.5 pmol cyclic GMP/s.
The biochemical and homology based modeling studies indicate that the secondary structure of the functional form of all membrane guanylate cyclases is homodimeric (Rondeau et al., 1995; Liu et al., 1997; Venkataraman et al., 2008). The contact points for their homo-dimeric formation reside in their extracellular domain (Misono et al., 2011) and in the intracellular domain within the highly conserved dimerization domain (Wilson and Chinkers, 1995) and core catalytic core domain (Venkataraman et al., 2008). The X-ray crystallographic studies have demonstrated that NCδ also exists as a dimer (Vijay-Kumar and Kumar, 1999). Thus, it was reasonable to expect that the Ca2+-modulated functional unit is NCδ dimer and ANF-RGC dimer.
This expectation was validated experimentally. When monomeric and dimeric forms of myristoylated NCδ were individually tested in reconstitution experiments for their abilities to stimulate ANF-RGC catalytic activity only the dimer was effective (Duda et al., 2012b). The stimulation by the monomeric form was only marginal, possibly resulting from spontaneous dimerization of the monomers when higher NCδ concentrations were used (Duda et al., 2012b). Thus indeed the functional Ca2+ signal transduction unit is composed of one NCδ dimer and one ANF-RGC dimer.
Neurocalcin δ targets directly the catalytic domain of ANF-RGC
The ANF-RGC fragment, aa 788–1029, encompassing the core catalytic domain, I820–G1029, was expressed as a soluble protein and tested for its basal and Ca2+-dependent modulated via NCδ activities. The protein exhibited intrinsic guanylate cyclase activity (18 ± 4 pmol cyclic GMP min-1 mg protein-1). This activity increased when Ca2+ and NCδ were added, and the increase was Ca2+ and NCδ-dose dependent (Duda et al., 2012b). Interestingly, the estimated EC50 for NCδ was comparable to that determined for full-length ANF-RGC strongly supporting the expectation that the NCδ signaling site resides within the catalytic domain.
The NCδ targeted site on ROS-GC1 was mapped to the aa segment V837–L858. The corresponding site on ANF-RGC, 849DIVGFTALSAESTPMQVVTLLMQ871, has 70% sequence conservation in comparison with ROS-GC1. When a synthetic peptide of this sequence was used in a functional interference experiment almost complete inhibition of the NCδ-stimulated ANF-RGC activity at 200 μM with an IC50 value of 80 μM was observed (Duda et al., 2012b). Because a scrambled peptide did not exhibit any inhibitory effect it was justified to conclude that the ANF-RGC region 849DIVGFTALSAESTPMQVVTLLMQ871 mediates NCδ-dependent Ca2+ stimulation of ANF-RGC activity. This region is a part of the core catalytic domain and common to the corresponding sites in other membrane guanylate cyclases28, it has a secondary structure of helix-loop-helix and is acidic in nature with a pI of 3.37 (Duda et al., 2012b).
The effects of ANF/ATP and Ca2+-neurocalcin δ signaling of ANF-RGC activity are multiplicative
To determine the liaison between ANF/ATP and Ca2+-NCδ signaling modes, ANF-RGC activity was analyzed first in the presence of 1 μM Ca2+ and 2 μM myristoylated NCδ and then with increasing concentrations, ranging from 10-11 M to 10-6 M, of ANF and constant 0.8 mM ATP. The presence of Ca2+ and NCδ resulted in stimulation of the cyclase activity approx. 3.5-fold above the basal activity. Addition of ANF and ATP resulted in additional 4.5-fold stimulation, demonstrating that the Ca2+-NCδ and ANF/ATP effects are multiplicative (Duda et al., 2012b). It is noteworthy that in the absence of Ca2+ in the reaction mixture only the ANF/ATP-dependent stimulation of ANF-RGC activity was observed.
The preceding narration on the mechanisms involved in the hormone- or Ca2+-NCδ-dependent stimulation of ANF-RGC activity explains the independence and multiplicativeness of the ANF and Ca2+-NCδ signals in the activation of ANF-RGC. It is based on our evolving conceptual scheme whose central idea is that the functional specificity of a guanylate cyclase is determined by the structure of its modular blocks. The structural motif, 669WTAPELL675 is involved in transmitting the ANF signal to the catalytic domain (Duda et al., 2009) but it is not involved in transmitting the Ca2+ signal to the catalytic domain; instead the 849DIVGFTALSAESTPMQVVTLLMQ871 motif is involved (Duda et al., 2012b).
PHYSIOLOGICAL VALIDATION OF THE TWO SIGNALING MECHANISMS OF THE ANF-RGC ACTIVATION
The two described above signaling mechanisms of ANF-RGC activation are depicted in Figure 3. It is obvious from their description that they were developed based solely on biochemical observations. And although biochemically well-proven, they would have to be considered only hypothetical until their validity was confirmed in vivo. And this validation is narrated below.
SIGNALING THROUGH THE 669WTAPELL675 MOTIF
In an in vitro reconstituted system the 669WTAPELL675 motif is critical for the transmission of the ANF/ATP signal and activation of the ANF-RGC catalytic domain and its absence results in unresponsiveness of the mutated ANF-RGC to the signal so if the same happens in vivo, an animal model in which the sequence coding for the 669WTAPELL675 motif is deleted from the ANF-RGC gene should be unresponsive to ANF and therefore exhibit all physiological consequences of this unresponsiveness. Following this logic, the 669WTAPELL675 sequence was deleted in genetically altered mice (Duda et al., 2013). It is worth mentioning that up till now it is the only ANF-RGC domain-specific genetically modified animal model.
In agreement with the in vitro determinations, basal ANF-RGC activity in the membranes of the heart, adrenal gland and kidney, the primary tissues where ANF-RGC is expressed, was practically indistinguishable between the wild type control (ANF-RGC669WTAPELL675+/+), heterozygous (ANF-RGC669WTAPELL675+/-) and homozygous (ANF-RGC669WTAPELL675-/-) mice (Duda et al., 2013). However, the mutated cyclase expressed in these tissues did not respond to ANF/ATP stimulation. The cyclase activity in the membranes of the homozygous mice was the same when assayed in the presence of 10-7 M ANF and 0.8 mM ATP as when assayed in their absence. Interestingly, for the heterozygous mice, the cyclase remained responsive to ANF/ATP but the maximal achieved activity oscillated around 50% of the wild type values, clearly showing that in the heterozygous mice where the product of one ANF-RGC gene copy is of the wild type and the other, of the deletion-mutated cyclase, only the wild type ANF-RGC is responsive to ANF/ATP and the mutant is not (Duda et al., 2013). Thus, the in vitro activity characteristics were the mirror images of these in vivo.
Almost identical values of basal guanylate cyclase activity in various tissues of the 669WTAPELL675 targeted mice and their isogenic controls implied that the expression of the mutant-cyclase must not differ from the expression of the wild type cyclase. This implication was confirmed by the results of immunocytochemical analyses. Side-by-side immunostaining with immunopurified anti ANF-RGC antibody resulted in identical images of the kidneys and adrenal glands of the wild type, heterozygous and homozygous 669WTAPELL675 targeted mice. Also, visual examination of the stained sections as well as of the respective differential interference contrast images indicated that the targeting of the 669WTAPELL675 motif does not change the integrity of these tissues (Duda et al., 2013).
The main function of ANF/ANF-RGC signaling system is to regulate natriuresis, diuresis, vasodilation, and prevent cardiac and renal hypertrophy. It regulates blood volume homeostasis and blood pressure by off-setting the renin-angiotensin-aldosterone system (RAAS): inhibiting renal renin secretion and aldosterone synthesis in the adrenocortical zona glomerulosa (Burnett et al., 1984; Brenner et al., 1990; Maack, 1996; Olson et al., 1998; Aoki et al., 2000; Shi et al., 2001). Therefore, elimination of ANF-RGC signaling through knocking-out either ANF-RGC or ANF gene leads to increased blood pressure, cardiac, and renal hypertrophy, fibrosis, to name some of the related pathological conditions (Dubois et al., 2000; Kishimoto et al., 2001; Ellmers et al., 2007; Das et al., 2010; Ellis et al., 2011; Pandey, 2011; Wadei and Textor, 2012). Since the 669WTAPELL675 targeted mice have partially (heterozygous) and fully (homozygous) suppressed ANF-RGC response to ANF, but the basal cyclase activity is unaffected the critical question was: does this suppression lead to increased blood pressure and other physiological alterations in the genetically modified mice?
The answer obtained was clearly “yes.” In comparison with the wild type the blood pressure of the heterozygous mice increased by ~37% and of the homozygous mice by ~56%. The increase was statistically highly significant with P value < 0.005 (Duda et al., 2013). It rose from 102 ± 9 mm Hg for the wild type mice to 134 ± 17 mm Hg for the heterozygous and 159 ± 11 mm Hg for the homozygous mice. These values showed that the progressive elevation of blood pressure directly correlates with the number of mutated ANF-RGC gene copies.
Because volume homeostasis and blood pressure are influenced by the mineralocorticoid hormone aldosterone secreted by the cells of the adrenocortical zona glomerulosa and the function of the ANF/ANF-RGC system is to inhibit this synthesis the obvious next question was whether the increased blood pressure in the 669WTAPELL675 targeted mice is a consequence of the inability of the mutated ANF-RGC to transduce the ANF signal and to synthesize cyclic GMP sufficient quantities to inhibit aldosterone synthesis? A hint was provided by studies on ANF-RGC knockout mice showing that these mice had increased aldosterone level (Zhao et al., 2007).
The plasma aldosterone concentrations were measured in both types of genetically modified mice (hetero- and homozygous) and in their isogenic controls (wild type). The results demonstrated that, in comparison with the wild type mice, the plasma aldosterone concentration increased by approximately 40% (from 147 ± 12 to 204 ± 18 pg/ml) in the plasma of the heterozygous mice (P < 0.005) and by approximately 75% (up to 256 ± 22 pg/ml) in the plasma of the homozygous mice (P < 0.005) (Duda et al., 2013).
Chronic pressure overload is almost always accompanied by cardiac hypertrophy (reviewed in Katholi and Couri, 2011). The same is observed in the 669WTAPELL675 targeted mice. The ratio of the heart weight (in mg) to whole body weight (in g) measured in 12 weeks old mice was 5.6 ± 0.3 and 6.1 ± 0.5 for the 669WTAPELL675(+/-) and 669WTAPELL675(-/-) mice, respectively, whereas it was 5 ± 0.3 for the wild type mice (Duda et al., 2013). However, hypertension is not the only cause of myocardial hypertrophy. Using animal models it has been shown that antihypertensive drugs do not always ameliorate cardiac hypertrophy (Knowles et al., 2001) and that even without systemic hypertension cardiac hypertrophy may occur (Oliver et al., 1997; Holtwick et al., 2003). Because deletion of the 669WTAPELL675 motif from ANF-RGC results in decreased synthesis of cyclic GMP it was hypothesized that cardiomyocytes of the 669WTAPELL675 targeted mice succumb to the insufficient quantities of cyclic GMP and normal inhibition of myocardial proliferative responses does not occur. Our ongoing studies indicate that indeed it is the case. The mice as young as 3 weeks of age (at weaning) exhibit significant cardiac hypertrophy. Which cyclic GMP-dependent signaling pathway involved in inhibition of myocardial proliferative responses is affected in these mice remains to be determined.
Taken together the biochemical and physiological evidence prove that the 669WTAPELL675 motif is critical for the ANF-RGC function as the transducer of the ANF/ATP signal.
NEUROCALCIN δ Ca2+-DEPENDENT SIGNALING OF ANF-RGC
To demonstrate that the ANF-RGC NCδ-Ca2+ signal transduction system is functional in vivo a mouse model with a disrupted NCδ gene was constructed and analyzed. Unfortunately, disruption of both copies of NCδ gene is lethal. Although it was unexpected at the time of developing the mouse line, it can be now understood in view of the results demonstrating that NCδ may be involved in spermatogenesis. Therefore, heterozygous, NCδ+/-, line is viable.
Because earlier studies from our laboratory and others’ had shown that NCδ is expressed in the adrenocortical zona glomerulosa (Nakano et al., 1993; Duda et al., 2012a) and that the adrenal gland also contains functional ANF-RGC transduction system (Takayanagi et al., 1987; Sharma et al., 1989; Duda et al., 1991; Rondeau et al., 1995) the adrenal gland appeared to be the tissue of choice for testing whether the ANF-RGC NCδ-Ca2+ signal transduction system is operational and of physiological significance there.
To show that NCδ is indeed the Ca2+-sensor modulator of ANF-RGC in the adrenal gland the particulate fractions of the adrenal glands from wild type and NCδ+/- mice and their isogenic controls (NCδ+/+) were tested for guanylate cyclase activity in the presence and absence of Ca2+. The activity in membranes isolated in the absence of Ca2+ was about 66 pmol cyclic GMP min-1 (mg protein) -1 for the control and NCδ+/- mice and the activity was not affected by the presence or absence of Ca2+ in the assay mixture. However, the activity in membranes isolated in the presence of Ca2+ was strongly dependent on the mice genotype and Ca2+ in the assay mixture. When assessed in the absence of Ca2+, the activity was ~70 pmol cyclic GMP min-1 (mg protein) -1 for the weight and NCδ+/- mice but when assessed in the presence of 1 μM Ca2+ the activity was 223 ± 20 pmol cyclic GMP min-1 (mg protein) -1 for the wild type mice and 135 ± 10 pmol cyclic GMP min-1 (mg protein) -1 for the NCδ+/- mice. Thus, the Ca2+-dependent NCδ-modulated ANF-RGC signaling pathway in the mice with one copy of NCδ gene deleted (NCδ+/-) is functionally half as active as in the wild type mice. To further authenticate that the lowering of the Ca2+-dependent cyclase activity in the adrenal gland membranes of NCδ+/- mice is the exclusive consequence of lower NCδ expression, 2 μM exogenous NCδ was added to the NCδ+/+ and NCδ+/- membranes (isolated in the presence of Ca2+) and the cyclase activity was determined in the presence of 1 μM Ca2+. The cyclase activity in the NCδ+/+ adrenal membranes increased only minimally, from 220 to 279 ± 21 pmol cyclic GMP min-1 (mg protein) -1 but in the NCδ+/- membranes, the increase was significantly larger, from 133 to 284 ± 24 (Duda et al., 2012b). Thus, the activity achieved was practically the same for both types of membranes. Hence, addition of exogenous NCδ to the NCδ+/- adrenal gland membranes restores the guanylate cyclase activity and brings it to the level of activity in the NCδ+/+ membranes. We rationalized that the slight activity increase in the NCδ+/+ membranes observed upon addition of exogenous NCδ is caused by a partial loss of the native NCδ during the membrane preparation.
What is the function of this pathway in the adrenal gland? In general, the primary role of ANF-RGC in the adrenal gland is to offset the renin-angiotensin system and inhibit aldosterone synthesis, and by doing this, to lower blood pressure (Burnett et al., 1984; Aoki et al., 2000; Shi et al., 2001). Therefore, is the Ca2+-dependent ANF-RGC signal transduction machinery in the adrenal gland involved in aldosterone synthesis? Our ongoing studies indicate that indeed it is. The plasma aldosterone levels in the NCδ+/- mice are approximately 27% higher than in the plasma of the control (NCδ+/+) mice. And the effect is exclusive for the aldosterone synthesizing glomerulosa cells, because corticosterone (synthesized in fasciculate cells) levels are unaffected by the absence of NCδ gene.
The increased plasma aldosterone level in the NCδ+/- mice correlates with the increase in blood pressure. Systolic blood pressure (measured by the non-invasive tail cuff method) was determined to be 92 ± 6 mm Hg for the wild type mice and 127 ± 9 mm Hg for the NCδ+/- mice. Therefore, the conclusion of these studies was that the ANF-RGC-Ca2+-NCδ transduction system is not only physically present but is of physiological significance at least in the adrenal gland.
In summary, this review has high-lighted studies which define the molecular and physiological mechanisms of the hormonal signal transduction of ANF-RGC. In addition, a new signal transduction mechanism and its present state of validation has been narrated. In this model Ca2+ is the additional signal of ANF-RGC. By entirely different mechanism, it regulates ANF-RGC catalytic activity and controls its physiological functions.
FUTURE DIRECTIONS
There are three venues through which, in these authors’ understanding, the future research will progress. The first venue is centered on the basic research to decipher (1) how the 669WTAPELL675 motif “communicates” with the catalytic domain of ANF-RGC and signals its activation and (2) the mechanism of NCδ-Ca2+ signaling of ANF-RGC activity. The second venue relates to the physiology of both ANF-RGC signaling pathways (1) establishing whether the Ca2+ signaling mechanism is operative in other tissues in addition to the adrenal gland and (2) to determine the interrelationship of the hormonal and Ca2+ pathways. Finally, after deciphering the molecular and physiological details of the two signaling pathway the third venue will be translational, to design a molecule that can target directly the catalytic domain and bring ANF-RGC to its full activity and prevent the pandemic of hypertension, myocardial hypertrophy and obesity. The last objective is the most far-reaching, but hopefully can be achieved after the first two goals are accomplished.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The numerous NIH and NSF support (Rameshwar K. Sharma) is acknowledged for the pioneering studies on ANF-RGC signal transduction field and the HL084584 and S82701 support (Teresa Duda) is acknowledged for the development of the 669WTAPELL675 and Ca2+ signaling mechanisms.
ABBREVIATIONS
- ANF
atrial natriuretic factor
- ANF-RGC
atrial natriuretic factor receptor guanylate cyclase
- ARM
ATP-regulatory module
- ATP
adenosine triphosphate
- BNP
B-type natriuretic peptide
- CNP
C-type natriuretic peptide
- CNP-RGC
C-type natriuretic peptide receptor guanylate cyclase
- cyclic AMP
3′,5′-cyclic adenosine monophosphate
- cyclic GMP
3′,5′-cyclic guanosine monophosphate
- CNG channel
cyclic nucleotide gated channel
- GCAP
guanylate cyclase activating protein
- GC-A
guanylate cyclase-A
- GC-B
guanylate cyclase-B
- GC-C
guanylate cyclase-C
- GC-D
guanylate cyclase-D
- GC-E
guanylate cyclase-E
- GC-F
guanylate cyclase-F
- GC-G
guanylate cyclase-G
- KHD
kinase homology domain
- K-LD
kinase-like domain
- NCδ
neurocalcin δ
- NPR-A
natriuretic peptide receptor-A
- ONE-GC
olfactory neuroepithelial guanylate cyclase
- STa-RGC
heat-stable enterotoxin (also guanylin and uroguanylin) receptor guanylate cyclase
- ROS-GC
rod outer segment guanylate cyclase
REFERENCES
- Aoki H., Richmond M., Izumo S., Sadoshima J. (2000). Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem. J. 347 275–284 10.1042/0264-6021:3470275 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bratová I., Otyepka M., KŘiž Z., KoŘa J. (2005). The mechanism of inhibition of the cyclin-dependent kinase-2 as revealed by the molecular dynamics study on the complex CDK2 with the peptide substrate HHASPRK. Protein Sci. 14 445–451 10.1110/ps.04959705 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brenner B. M., Ballermann B. J., Gunning M. E., Zeidel M. L. (1990). Diverse biological actions of atrial natriuretic peptide. Physiol. Rev. 7 665–669 [DOI] [PubMed] [Google Scholar]
- Burczynska B., Duda T., Sharma R. K. (2007). ATP signaling site in the ARM domain of atrial natriuretic factor receptor guanylate cyclase. Mol. Cell. Biochem. 301 193–207 10.1007/s11010-006-9400-7 [DOI] [PubMed] [Google Scholar]
- Burnett J. C. Jr., Granger J. P., Opgenorth T. J. (1984). Effect of synthetic atrial natriuretic factor on renal function and rennin release. Am. J. Physiol. 247 F863–F866 [DOI] [PubMed] [Google Scholar]
- Chang C. H., Kohse K. P., Chang B., Hirata M., Jiang B., Douglas J. E., et al. (1990). Characterization of ATP-stimulated guanylate cyclase activation in rat lung membranes. Biochim. Biophys. Acta 1052 159–165 10.1016/0167-4889(90)90071-K [DOI] [PubMed] [Google Scholar]
- Chang M. S., Lowe D. G., Lewis M., Hellmiss R., Chen E., Goeddel D. V. (1989). Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 341 68–72 10.1038/341068a0 [DOI] [PubMed] [Google Scholar]
- Chao Y.-C., Cheng C.-J., Hsieh H.-T., Lin C.-C., Chen C.-C., Yang R.-B. (2010). Guanylate cyclase-G, expressed in the Grueneberg ganglion olfactory subsystem, is activated by bicarbonate. Biochem. J. 432 267–273 10.1042/BJ20100617 [DOI] [PubMed] [Google Scholar]
- Chinkers M., Garbers D. L. (1989). The protein kinase domain of the ANP receptor is required for signaling. Science 245 1392–1394 10.1126/science.2571188 [DOI] [PubMed] [Google Scholar]
- Chinkers M., Garbers D. L., Chang M. S., Lowe D. G., Chin H. M., Goeddel D. V., et al. (1989). A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 338 78–83 10.1038/338078a0 [DOI] [PubMed] [Google Scholar]
- Chinkers M., Singh S., Garbers D. L. (1991). Adenine nucleotides are required for activation of rat atrial natriuretic peptide receptor/guanylyl cyclase expressed in a baculovirus system. J. Biol. Chem. 266 4088–4093 [PubMed] [Google Scholar]
- Cole F. E., Rondon I., Iwata T., Hardee E., Frohlich E. D. (1989). Effect of ATP and amiloride on ANF binding and stimulation of cyclic GMP accumulation in rat glomerular membranes. Life Sci. 45 477–484 10.1016/0024-3205(89)90097-0 [DOI] [PubMed] [Google Scholar]
- Coussen F., Mulle C. (2006). Kainate receptor-interacting proteins and membrane trafficking. Biochem. Soc. Trans. 34 927–930 10.1042/BST0340927 [DOI] [PubMed] [Google Scholar]
- Das S., Au E., Krazit S. T., Pandey K. N. (2010). Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: role of proinflammatory cytokines. Endocrinology 151 5841–5850 10.1210/en.2010-0655 [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Bold A. J. (1985). Atrial natriuretic factor: a hormone produced by the heart. Science 230 767–770 10.1126/science.2932797 [DOI] [PubMed] [Google Scholar]
- de Sauvage F. J., Camerato T. R., Goeddel D. V. (1991). Primary structure and functional expression of the human receptor for Escherichia coli heat-stable enterotoxin. J. Biol. Chem. 266 17912–17918 [PubMed] [Google Scholar]
- Detwiler P. (2000). Open the loop: dissecting feedback regulation of a second messenger transduction cascade. Neuron 36 3–4 10.1016/S0896-6273(02)00940-6 [DOI] [PubMed] [Google Scholar]
- Dizhoor A. M., Olshevskaya E. V., Henzel W. J., Wong S. C., Stults J. T., Ankoudinova I., et al. (1995). Cloning, sequencing, and expression of a 24-kDa Ca2+-binding protein activating photoreceptor guanylyl cyclase. J. Biol. Chem. 270 25200–25206 10.1074/jbc.270.42.25200 [DOI] [PubMed] [Google Scholar]
- Dubois S. K., Kishimoto I., Lillis T. O., Garbers D. L. (2000). A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function. Proc. Natl. Acad. Sci. U.S.A. 97 4369–4373 10.1073/pnas.97.8.4369 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Bharill S., Wojtas I., Yadav P., Gryczynski I., Gryczynski Z., et al. (2009). Atrial natriuretic factor receptor guanylate cyclase signaling: new ATP-regulated transduction motif. Mol. Cell. Biochem. 324 39–53 10.1007/s11010-008-9983-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Fik-Rymarkiewicz E., Venkataraman V., Krishnan A., Sharma R. K. (2004). Calcium-modulated ciliary membrane guanylate cyclase transduction machinery: constitution and operational principles. Mol. Cell. Biochem. 267 107–122 10.1023/B:MCBI.0000049372.33965.4f [DOI] [PubMed] [Google Scholar]
- Duda T., Goraczniak R. M., Sharma R. K. (1991). Site-directed mutational analysis of a membrane guanylate cyclase cDNA reveals the atrial natriuretic factor signaling site. Proc. Natl. Acad. Sci. U.S.A. 88 7882–7886 10.1073/pnas.88.17.7882 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Goraczniak R. M., Sharma R. K. (1993a). The glycine residue of ATP regulatory module in receptor guanylate cyclases that is essential in natriuretic factor signaling. FEBS Lett. 335 309–314 10.1016/0014-5793(93)80408-M [DOI] [PubMed] [Google Scholar]
- Duda T., Goraczniak R. M., Sitaramayya A., Sharma R. K. (1993b). Cloning and expression of an ATP-regulated human retina C-type natriuretic factor receptor guanylate cyclase. Biochemistry 32 1391–1395 10.1021/bi00057a001 [DOI] [PubMed] [Google Scholar]
- Duda T., Goraczniak R. M., Sharma R. K. (1996a). Molecular characterization of S100A1-S100B protein in retina and its activation mechanism of bovine photoreceptor guanylate cyclase. Biochemistry 35 6263–6266 10.1021/bi960007m [DOI] [PubMed] [Google Scholar]
- Duda T., Goraczniak R., Surgucheva I., Rudnicka-Nawrot M., Gorczyca W. A., Palczewski K., et al. (1996b). Calcium modulation of bovine photoreceptor guanylate cyclase. Biochemistry 35 8478–8482 10.1021/bi960752z [DOI] [PubMed] [Google Scholar]
- Duda T., Jankowska A., Venkataraman V., Nagele R. G., Sharma R. K. (2001a). A novel calcium-regulated membrane guanylate cyclase transduction system in the olfactory neuroepithelium. Biochemistry 40 12067–12077 10.1021/bi0108406 [DOI] [PubMed] [Google Scholar]
- Duda T., Yadav P., Jankowska A., Venkataraman V., Sharma R. K. (2001b). Three dimensional atomic model and experimental validation for the ATP-Regulated Module (ARM) of the atrial natriuretic factor receptor guanylate cyclase. Mol. Cell. Biochem. 217 165–172 10.1023/A:1007236917061 [DOI] [PubMed] [Google Scholar]
- Duda T., Krishnan R., Sharma R. K. (2006). GCAP1: antithetical calcium sensor of ROS-GC transduction machinery. Calcium Bind. Proteins 1 102–107 [Google Scholar]
- Duda T., Pertzev A., Koch K. W., Sharma R. K. (2012a). Antithetical modes of and the Ca2+ sensors targeting in ANF-RGC and ROS-GC1 membrane guanylate cyclases. Front. Mol. Neurosci. 5:44. 10.3389/fnmol.2012.00044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Pertzev A., Sharma R. K. (2012b). Ca(2+) modulation of ANF-RGC: new signaling paradigm interlocked with blood pressure regulation. Biochemistry 51 9394–9405 10.1021/bi301176c [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Pertzev A., Sharma R. K. (2013). The ANF-RGC gene motif (669)WTAPELL(675) is vital for blood pressure regulation: Biochemical mechanism. Biochemistry 52 2337–2334 10.1021/bi400175d [DOI] [PMC free article] [PubMed] [Google Scholar]
- Duda T., Sharma R. K. (1995). ATP bimodal switch that regulates the ligand binding and signal transduction activities of the atrial natriuretic factor receptor guanylate cyclase. Biochem. Biophys. Res. Commun. 209 286–292 10.1006/bbrc.1995.1501 [DOI] [PubMed] [Google Scholar]
- Duda T., Sharma R. K. (2005). Two membrane juxtaposed signaling modules in ANF-RGC are interlocked. Biochem. Biophys. Res. Commun. 332 149–156 10.1016/j.bbrc.2005.04.102 [DOI] [PubMed] [Google Scholar]
- Duda T., Sharma R. K. (2008). ONE-GC membrane guanylate cyclase, a trimodal odorant signal transducer. Biochem. Biophys. Res. Commun. 367 440–444 10.1016/j.bbrc.2007.12.153 [DOI] [PubMed] [Google Scholar]
- Duda. T., Sharma R. K. (2009). Ca2+-modulated ONE-GC odorant signal transduction. FEBS Lett. 583 1327–1330 10.1016/j.febslet.2009.03.036 [DOI] [PubMed] [Google Scholar]
- Duda T., Venkataraman V., Ravichandran S., Sharma R. K. (2005). ATP-regulated module (ARM) of the atrial natriuretic factor receptor guanylate cyclase. Peptides 26 969–984 10.1016/j.peptides.2004.08.032 [DOI] [PubMed] [Google Scholar]
- Duda T., Yadav P., Sharma R. K. (2011). Allosteric modification, the primary ATP activation mechanism of atrial natriuretic factor receptor guanylate cyclase. Biochemistry 50 1213–1212 10.1021/bi1018978 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ellis K. L., Newton-Cheh C., Wang T. J., Frampton C. M., Doughty R. N., Whalley G. A., et al. (2011). Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J. Mol. Cell. Cardiol. 50 695–701 10.1016/j.yjmcc.2011.01.010 [DOI] [PubMed] [Google Scholar]
- Ellmers L. J., Scott N. J., Piuhola J., Maeda N., Smithies O., Frampton C. M., et al. (2007). Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J. Mol. Endocrinol. 38 245–257 10.1677/jme.1.02138 [DOI] [PubMed] [Google Scholar]
- Foster D. C., Garbers D. L. (1998). Dual role for adenine nucleotides in the regulation of the atrial natriuretic peptide receptor, guanylyl cyclase-A. J. Biol. Chem. 273 16311–16318 10.1074/jbc.273.26.16311 [DOI] [PubMed] [Google Scholar]
- Fulle H. J., Vassar R., Foster D. C., Yang R. B., Axel R., Garbers D. L. (1995). A receptor guanylyl cyclase expressed specifically in olfactory sensory neurons. Proc. Natl. Acad. Sci. U.S.A. 92 3571–3575 10.1073/pnas.92.8.3571 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goraczniak R. M., Duda T., Sharma R. K. (1992). A structural motif that defines the ATP-regulatory module of guanylate cyclase in atrial natriuretic factor signalling. Biochem. J. 282 533–537 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goraczniak R. M., Duda T., Sharma R. K. (1998). Calcium modulated signaling site in type 2 rod outer segment membrane guanylate cyclase (ROS-GC2). Biochem. Biophys. Res. Commun. 245 447–453 10.1006/bbrc.1998.8455 [DOI] [PubMed] [Google Scholar]
- Goraczniak R. M., Duda T., Sitaramayya A., Sharma R. K. (1994). Structural and functional characterization of the rod outer segment membrane guanylate cyclase. Biochem. J. 302 455–461 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hamra F. K., Forte L. R., Eber S. L., Pidhorodeckyj N. V., Krause W. J., Freeman R. H., et al. (1993). Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 90 10464–10468 10.1073/pnas.90.22.10464 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hanks S. K., Quinn A. M., Hunter T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241 42–52 10.1126/science.3291115 [DOI] [PubMed] [Google Scholar]
- He X., Nishio K., Misono K. S. (1995). High-yield affinity alkylation of the atrial natriuretic factor receptor binding site. Bioconjug. Chem. 6 541–548 10.1021/bc00035a007 [DOI] [PubMed] [Google Scholar]
- Holtwick R., van Eickels M., Skryabin B. V., Baba H. A., Bubikat A., Begrow F., et al. (2003). Pressure independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanyly cyclase-A. J. Clin. Invest. 111 1399–1407 10.1172/JCI17061 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huo X., Abe T., Misono K. S. (1999). Ligand binding-dependent limited proteolysis of the atrial natriuretic peptide receptor: juxtamembrane hinge structure essential for transmembrane signal transduction. Biochemistry 38 16941–16951 10.1021/bi9919448 [DOI] [PubMed] [Google Scholar]
- Iino S., Kobayashi S., Okazaki K., Hidaka H. (1995). Immunohistochemical localization of neurocalcin in the rat inner ear. Brain Res. 680 128–134 10.1016/0006-8993(95)00253-M [DOI] [PubMed] [Google Scholar]
- Ivings L., Pennington S. R., Jenkins R., Weiss J. L., Burgoyne R. D. (2002). Identification of Ca2+-dependent binding partners for the neuronal calcium sensor protein neurocalcin delta: interaction with actin, clathrin and tubulin. Biochem. J. 363 599–608 10.1042/0264-6021:3630599 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Katholi R. E., Couri D. M. (2011). Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int. J. Hypertens. 2011 495349 10.4061/2011/495349 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khare S., Wilson D., Wali R. K., Tien X. Y., Bissonnette M., Niedziela S. M., et al. (1994). Guanylin activates rat colonic particulate guanylate cyclase. Biochem. Biophys. Res. Commun. 203 1432–1437 10.1006/bbrc.1994.2345 [DOI] [PubMed] [Google Scholar]
- Kishimoto I., Rossi K., Garbers D. L. (2001). A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 98 2703–2706 10.1073/pnas.051625598 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knowles J. W., Esposito G., Mao L., Hagaman J. R., Fox J. E., Smithies O., et al. (2001). Pressure independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107 975–984 10.1172/JCI11273 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koch K.-W. (1991). Purification and identification of photoreceptor guanylate cyclase. J. Biol. Chem. 266 8634–8637 [PubMed] [Google Scholar]
- Koch K.-W., Duda T., Sharma R. K. (2010). Ca2+-modulated vision-linked ROS-GC guanylate cyclase transduction machinery. Mol. Cell. Biochem. 334 105–115 10.1007/s11010-009-0330-z [DOI] [PubMed] [Google Scholar]
- Kuhn M., Ng C. K., Su Y. H., Kilić A., Mitko D., Bien-Ly N., et al. (2004). Identification of an orphan guanylate cyclase receptor selectively expressed in mouse testis. Biochem. J. 379 385–393 10.1042/BJ20031624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kumar V. D., Vijay-Kumar S., Krishnan A., Duda T., Sharma R. K. (1999). A second calcium regulator of rod outer segment membrane guanylate cyclase, ROS-GC1: neurocalcin. Biochemistry 38 12614–12620 10.1021/bi990851n [DOI] [PubMed] [Google Scholar]
- Krishnan A., Venkataraman V., Fik-Rymarkiewicz E., Duda T., Sharma R. K. (2004). Structural, biochemical, and functional characterization of the calcium sensor neurocalcin delta in the inner retinal neurons and its linkage with the rod outer segment membrane guanylate cyclase transduction system. Biochemistry 43 2708–2723 10.1021/bi035631v [DOI] [PubMed] [Google Scholar]
- Kuno T., Andresen J. W., Kamisaki Y., Waldman S. A., Chang L. Y., Saheki S., et al. (1986). Co-purification of an atrial natriuretic factor receptor and particulate guanylate cyclase from rat lung. J. Biol. Chem. 261 5817–5823 [PubMed] [Google Scholar]
- Kurose H., Inagami T., Ui M. (1987). Participation of adenosine 5′-triphosphate in the activation of membrane-bound guanylate cyclase by the atrial natriuretic factor. FEBS Lett. 219 375–379 10.1016/0014-5793(87)80256-9 [DOI] [PubMed] [Google Scholar]
- Labrecque J., Deschênes J., McNicoll N, De Léan A. (2001). Agonistic induction of a covalent dimer in a mutant of natriuretic peptide receptor-A documents a juxtamembrane interaction that accompanies receptor activation. J. Biol. Chem. 276 8064–8072 10.1074/jbc.M005550200 [DOI] [PubMed] [Google Scholar]
- Labrecque J., Mc Nicoll N., Marquis M, De Lean A. (1999). A disulfide-bridged mutant of natriuretic peptide receptor-A displays constitutive activity. Role of receptor dimerization in signal transduction. J. Biol. Chem. 274 9752–9759 10.1074/jbc.274.14.9752 [DOI] [PubMed] [Google Scholar]
- Ladant D. (1995). Calcium and membrane binding properties of bovine neurocalcin delta expressed in Escherichia coli. J. Biol. Chem. 270 3179–3185 [PubMed] [Google Scholar]
- Larose L., McNicoll N., Ong H, De Léan A. (1991). Allosteric modulation by ATP of the bovine adrenal natriuretic factor R1 receptor functions. Biochemistry 30 8990–8995 10.1021/bi00101a012 [DOI] [PubMed] [Google Scholar]
- Leinders-Zufall T., Cockerham R. E., Michalakis S., Biel M., Garbers D. L., Reed R. R., et al. (2007). Contribution of the receptor guanylyl cyclase GC-D to chemosensory function in the olfactory epithelium. Proc. Natl. Acad. Sci. U.S.A. 104 14507–14512 10.1073/pnas.0704965104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu Y., Ruoho A. E., Rao V. D., Hurley J. H. (1997). Catalytic mechanism of the adenylyl and guanylyl cyclases: modeling and mutational analysis. Proc. Natl. Acad. Sci. U.S.A. 94 13414–13419 10.1073/pnas.94.25.13414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lowe D. G., Chang M. S., Hellmiss R., Chen E., Singh S., Garbers D. L., et al. (1989). Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 8 1377–13784 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lowe D. G., Dizhoor A. M., Liu K., Gu Q., Spencer M., Laura R., et al. (1995). Cloning and expression of a second photoreceptor-specific membrane retina guanylyl cyclase (RetGC), RetGC-2. Proc. Natl. Acad. Sci. U.S.A. 92 5535–5539 10.1073/pnas.92.12.5535 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maack T. (1996). Role of atrial natriuretic factor in volume control. Kidney Int. 49 1732–1737 10.1038/ki.1996.257 [DOI] [PubMed] [Google Scholar]
- Mamasuew K., Breer H., Fleischer J. (2008). Gruenberg ganglion neurons respond to cool ambient temperatures. Eur. J. Neurosci. 28 1775–1785 10.1111/j.1460-9568.2008.06465.x [DOI] [PubMed] [Google Scholar]
- Marala R., Duda T., Goraczniak R. M., Sharma R. K. (1992). Genetically tailored atrial natriuretic factor-dependent guanylate cyclase. Immunological and functional identity with 180 kDa membrane guanylate cyclase and ATP signaling site. FEBS Lett. 296 254–258 10.1016/0014-5793(92)80298-U [DOI] [PubMed] [Google Scholar]
- Marala R. B., Sitaramayya A., Sharma R. K. (1991). Dual regulation of atrial natriuretic factor-dependent guanylate cyclase activity by ATP. FEBS Lett. 281 73–76 10.1016/0014-5793(91)80361-6 [DOI] [PubMed] [Google Scholar]
- Margulis A., Pozdnyakov N., Sitaramayya A. (1996). Activation of bovine photoreceptor guanylate cyclase by S100 proteins. Biochem. Biophys. Res. Commun. 218 243–247 10.1006/bbrc.1996.0043 [DOI] [PubMed] [Google Scholar]
- McNicoll N., Escher E., Wilkes B. C., Schiller P. W., Ong H, De Léan A. (1992). Highly efficient photoaffinity labeling of the hormone binding domain of atrial natriuretic factor receptor. Biochemistry 31 4487–4493 10.1021/bi00133a015 [DOI] [PubMed] [Google Scholar]
- McNicoll N., Gagnon J., Rondeau J. J., Ong H, De Léan A. (1996). Localization by photoaffinity labeling of natriuretic peptide receptor-A binding domain. Biochemistry 35 12950–12956 10.1021/bi960818q [DOI] [PubMed] [Google Scholar]
- Meloche S., McNicoll N., Liu B., Ong H, De Lean A. (1988). Atrial natriuretic factor R1 receptor from bovine adrenal zona glomerulosa: purification, characterization, and modulation by amiloride. Biochemistry 27 8151–8158 10.1021/bi00421a025 [DOI] [PubMed] [Google Scholar]
- Miao Z. H., Song D. L., Douglas J. G., Chang C. H. (1995). Mutational inactivation of the catalytic domain of guanylate cyclase-A receptor. Hypertension 25 694–698 10.1161/01.HYP.25.4.694 [DOI] [PubMed] [Google Scholar]
- Misono K. S. (2002). Natriuretic peptide receptor: structure and signaling. Mol. Cell. Biochem. 230 49–60 10.1023/A:1014257621362 [DOI] [PubMed] [Google Scholar]
- Misono K. S., Ogawa H., Qiu Y., Ogata C. M. (2005). Structural studies of the natriuretic peptide receptor: a novel hormone-induced rotation mechanism for transmembrane signal transduction. Peptides 26 957–968 10.1016/j.peptides.2004.12.021 [DOI] [PubMed] [Google Scholar]
- Misono K. S., Philo J. S., Arakawa T., Ogata C. M., Qiu Y., Ogawa H., et al. (2011). Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. FEBS J. 278 1818–1829 10.1111/j.1742-4658.2011.08083.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miyagi M., Misono K. S. (2000). Disulfide bond structure of the atrial natriuretic peptide receptor extracellular domain: conserved disulfide bonds among guanylate cyclase-coupled receptors. Biochim. Biophys. Acta 1478 30–38 10.1016/S0167-4838(00)00002-9 [DOI] [PubMed] [Google Scholar]
- Nakano A., Terasawa M., Watanabe M., Okazaki K., Inoue S., Kato M., et al. (1993). Distinct regional localization of neurocalcin, a Ca2+-binding protein, in the bovine adrenal gland. J. Endocrinol. 138 283–290 10.1677/joe.0.1380283 [DOI] [PubMed] [Google Scholar]
- Ogawa H., Qiu Y., Huang L., Tam-Chang S. W., Young H. S., Misono K. S. (2009). Structure of the atrial natriuretic peptide receptor extracellular domain in the unbound and hormone-bound states by single-particle electron microscopy. FEBS J. 276 1347–1355 10.1111/j.1742-4658.2009.06870.x [DOI] [PubMed] [Google Scholar]
- Ogawa H., Qiu Y., Ogata C. M., Misono K. S. (2004). Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain: rotation mechanism for transmembrane signal transduction. J. Biol. Chem. 279 28625–28631 10.1074/jbc.M313222200 [DOI] [PubMed] [Google Scholar]
- Ogawa H., Zhang X., Qiu Y., Ogata C. M., Misono K. S. (2003). Crystallization and preliminary X-ray analysis of the atrial natriuretic peptide (ANP) receptor extracellular domain complex with ANP: use of ammonium sulfate as the cryosalt. Acta Crystallogr. D Biol. Crystallogr. 59 1831–1833 10.1107/S0907444903016445 [DOI] [PubMed] [Google Scholar]
- Okazaki K., Obata N. H., Inoue S., Hidaka H. (1995). S100 beta is a target protein of neurocalcin delta, an abundant isoform in glial cells. Biochem. J. 306 551–555 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oliver P. M., Fox J. E., Kim R., Rockman H. A., Kim H. S., Reddick R. L., et al. (1997). Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. U.S.A. 94 14730–14735 10.1073/pnas.94.26.14730 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olson L. J., Ho B., Cashdollar L. W., Drewett J. G. (1998). Functionally active catalytic domain is essential of guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis. Mol. Pharmacol. 54 761–769 [DOI] [PubMed] [Google Scholar]
- Palczewski K., Subbaraya I., Gorczyca W. A., Helekar B. S., Ruiz C. C., Ohguro H., et al. (1994). Molecular cloning and characterization of retinal photoreceptor guanylyl cyclase-activating protein. Neuron 13 395–404 10.1016/0896-6273(94)90355-7 [DOI] [PubMed] [Google Scholar]
- Pandey K. N. (2011). Guanylyl cyclase/atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. Can. J. Physiol. Pharmacol. 89 557–573 10.1139/y11-054 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pandey K. N., Singh S. (1990). Molecular cloning and expression of murine guanylate cyclase/atrial natriuretic factor receptor cDNA. J. Biol. Chem. 265 12342–12348 [PubMed] [Google Scholar]
- Parat M., Blanchet J, De Léan A. (2010). Role of juxtamembrane and transmembrane domains in the mechanism of natriuretic peptide receptor A activation. Biochemistry 49 4601–4610 10.1021/bi901711w [DOI] [PubMed] [Google Scholar]
- Paul A. K. (1986). Particulate Guanylate Cyclase from Adrenocortical Carcinoma 494. Purification, Biochemical and Immunological Characterization. Ph.D. thesis, University of Tennessee [Google Scholar]
- Paul A. K., Marala R. B., Jaiswal R. K., Sharma R. K. (1987). Coexistence of guanylate cyclase and atrial natriuretic factor receptor in a 180-kD protein. Science 235 1224–1226 10.1126/science.2881352 [DOI] [PubMed] [Google Scholar]
- Pertzev A., Duda T., Sharma R. K. (2010). Ca2+ sensor GCAP1: a constitutive element of the ONE-GC-modulated odorant signal transduction pathway. Biochemistry 49 7303–7313 10.1021/bi101001v [DOI] [PMC free article] [PubMed] [Google Scholar]
- Potter L. R., Hunter T. (1998a). Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol. Cell. Biol. 18 2164–2172 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Potter L. R., Hunter T. (1998b). Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor. J. Biol. Chem. 273 15533–15539 10.1074/jbc.273.25.15533 [DOI] [PubMed] [Google Scholar]
- Potter L. R., Hunter T. (1999a). Identification and characterization of the phosphorylation sites of the guanylyl cyclase-linked natriuretic peptide receptors A and B. Methods 19 506–520 10.1006/meth.1999.0893 [DOI] [PubMed] [Google Scholar]
- Potter L. R., Hunter T. (1999b). A constitutively ``phosphorylated'' guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization. Mol. Biol. Cell 10 1811–1820 10.1091/mbc.10.6.1811 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pozdnyakov N., Yoshida A., Cooper N. G., Margulis A., Duda T., Sharma R. K., et al. (1995). A novel calcium-dependent activator of retinal rod outer segment membrane guanylate cyclase. Biochemistry 34 14279–14283 10.1021/bi00044a002 [DOI] [PubMed] [Google Scholar]
- Pugh E. N. Jr., Duda T., Sitaramayya A., Sharma R. K. (1997). Photoreceptor guanylate cyclases: a review. Biosci. Rep. 17 429–473 10.1023/A:1027365520442 [DOI] [PubMed] [Google Scholar]
- Rebello M. R., Aktas A., Medler K. F. (2011). Expression of calcium binding proteins in mouse type II taste cells. J. Histochem. Cytochem. 59 530–539 10.1369/0022155411402352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rondeau J. J., McNicoll N., Gagnon J., Bouchard N., Ong H, De Léan A. (1995). Stoichiometry of the atrial natriuretic factor-R1 receptor complex in the bovine zona glomerulosa. Biochemistry 34 2130–2136 10.1021/bi00007a005 [DOI] [PubMed] [Google Scholar]
- Schulz S., Green C. K., Yuen P. S., Garbers D. L. (1990). Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 63 941–948 10.1016/0092-8674(90)90497-3 [DOI] [PubMed] [Google Scholar]
- Schulz S., Singh S., Bellet R. A., Singh G., Tubb D. J., Chin H., et al. (1989). The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell 58 1155–1162 10.1016/0092-8674(89)90513-8 [DOI] [PubMed] [Google Scholar]
- Schulz S., Wedel B. J., Matthews A., Garbers D. L. (1998). The cloning and expression of a new guanylyl cyclase orphan receptor. J. Biol. Chem. 273 1032–1037 10.1074/jbc.273.2.1032 [DOI] [PubMed] [Google Scholar]
- Sharma R. K. (2002). Evolution of the membrane guanylate cyclase transduction system. Mol. Cell. Biochem. 230 3–30 10.1023/A:1014280410459 [DOI] [PubMed] [Google Scholar]
- Sharma R. K. (2010). Membrane guanylate cyclase is a beautiful signal transduction machine: overview. Mol. Cell. Biochem. 334 3–36 10.1007/s11010-009-0336-6 [DOI] [PubMed] [Google Scholar]
- Sharma R. K., Duda T. (2010). Odorant-linked ROS-GC subfamily membrane guanylate cyclase transduction system. Mol. Cell. Biochem. 334 181–189 10.1007/s11010-009-0333-9 [DOI] [PubMed] [Google Scholar]
- Sharma R. K., Jaiswal R. K., Duda T. (1988a). ``Second messenger role of cyclic GMP in atrial natriuretic factor receptor mediated signal transduction: 180 kDa membrane guanylate cyclase, its coupling with atrial natriuretic factor receptor and its regulation by protein kinase C,'' in Biological and Molecular Aspects of Atrial Factors ed. Needleman (New york:Alan R. Liss, Inc.) 77–96 [Google Scholar]
- Sharma R. K., Marala R. B., Paul A. K. (1988b). ``Mediatory role of cyclic GMP in receptor-mediated signal transduction: membrane guanylate cyclase and its coupling with atrial natriuretic factor receptor,'' in American Society of Hypertension Symposium Series, Advances in Peptide Research, Vol 2 eds Brenner B. M., Laragh J. H. (New York:Raven Press; ) 61–77 [Google Scholar]
- Sharma R. K., Marala R. B., Duda T. (1989). Purification and characterization of the 180-kDa membrane guanylate cyclase containing atrial natriuretic factor receptor from rat adrenal gland and its regulation by protein kinase C. Steroids 53 437–460 10.1016/0039-128X(89)90024-X [DOI] [PubMed] [Google Scholar]
- Sharma R. K., Yadav P., Duda T. (2001). Allosteric regulatory step and configuration of the ATP-binding pocket in atrial natriuretic factor receptor guanylate cyclase transduction mechanism. Can. J. Physiol. Pharmacol. 79 682–691 10.1139/y01-033 [DOI] [PubMed] [Google Scholar]
- Shi S.-J, Nguyen H. T., Sharma G. D., Navar G., Pandey K. N. (2001). Genetic disruption of atrial natriuretic peptide receptor-A alters rennin and angiotensinII levels. Am. J. Physiol. Renal Physiol. 281 F665–F673 [DOI] [PubMed] [Google Scholar]
- Shyjan A. W., de Sauvage F. J., Gillett N. A., Goeddel D. V., Lowe D. G. (1992). Molecular cloning of a retina-specific membrane guanylyl cyclase. Neuron 9 727–737 10.1016/0896-6273(92)90035-C [DOI] [PubMed] [Google Scholar]
- Singh S., Singh G., Heim J. M., Gerzer R. (1991). Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line. Biochem. Biophys. Res. Commun. 179 1455–1463 10.1016/0006-291X(91)91736-V [DOI] [PubMed] [Google Scholar]
- Takayanagi R., Inagami T., Snajdar R. M., Imada T., Tamura M., Misono K. S. (1987). Two distinct forms of receptors for atrial natriuretic factor in bovine adrenocortical cells. Purification, ligand binding, and peptide mapping. J. Biol. Chem. 262 12104–12113 [PubMed] [Google Scholar]
- Thompson D. K., Garbers D. L. (1995). Dominant negative mutations of the guanylyl cyclase-A receptor. Extracellular domain deletion and catalytic domain point mutations. J. Biol. Chem. 270 425–430 10.1074/jbc.270.1.425 [DOI] [PubMed] [Google Scholar]
- Thorpe D. S., Morkin E. (1990). The carboxyl region contains the catalytic domain of the membrane form of guanylate cyclase. J. Biol. Chem. 265 14717–14720 [PubMed] [Google Scholar]
- Thorpe D. S., Niu S., Morkin E. (1996). The guanylyl cyclase core of an atrial natriuretic peptide receptor: enzymatic properties and basis for cooperativity. Biochem. Biophys. Res. Commun. 218 670–673 10.1006/bbrc.1996.0120 [DOI] [PubMed] [Google Scholar]
- Tremblay J., Huot C., Koch C., Potier M. (1991). Characterization of the functional domains of the natriuretic peptide receptor/guanylate cyclase by radiation inactivation. J. Biol. Chem. 266 8171–8175 [PubMed] [Google Scholar]
- Tucker C. L., Hurley J. H., Miller T. R., Hurley J. B. (1998). Two amino acid substitutions convert a guanylyl cyclase, RetGC-1, into an adenylyl cyclase. Proc. Natl. Acad. Sci. U.S.A. 95 5993–5997 10.1073/pnas.95.11.5993 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Venkataraman V., Duda T., Ravichandran S., Sharma R. K. (2008). Neurocalcin delta modulation of ROS-GC1, a new model of Ca2+ signaling. Biochemistry 47 6590–6601 10.1021/bi800394s [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vijay-Kumar S., Kumar V. D. (1999). Crystal structure of recombinant bovine neurocalcin. Nat. Struct. Biol. 6 80–88 10.1038/4956 [DOI] [PubMed] [Google Scholar]
- Wadei H. M., Textor S. C. (2012). The role of the kidney in regulating arterial blood pressure. Nat. Rev. Nephrol. 8 602–609 10.1038/nrneph.2012.191 [DOI] [PubMed] [Google Scholar]
- Wedel B. J., Foster D. C., Miller D. E., Garbers D. L. (1997). A mutation of the atrial natriuretic peptide (guanylyl cyclase-A) receptor results in a constitutively hyperactive enzyme. Proc. Natl. Acad. Sci. U.S.A. 94 459–462 10.1073/pnas.94.2.459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wedel B. J., Garbers D. L. (1997). New insights on the functions of the guanylyl cyclase receptors. FEBS Lett. 410 29–33 10.1016/S0014-5793(97)00358-X [DOI] [PubMed] [Google Scholar]
- Wen X. H., Duda T., Pertzev A., Venkataraman V., Makino C. L., Sharma R. K. (2012). S100B serves as a Ca2+ sensor for ROS-GC1 guanylate cyclase in cones but not in rods of the murine retina. Cell. Physiol. Biochem. 29 417–430 10.1159/000338496 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wierenga R. K., Hol W. G. (1983). Predicted nucleotide-binding properties of p21 protein and its cancer-associated variant. Nature 302 842–844 10.1038/302842a0 [DOI] [PubMed] [Google Scholar]
- Wilson E. M., Chinkers M. (1995). Identification of sequences mediating guanylyl cyclase dimerization. Biochemistry 34 4696–4701 10.1021/bi00014a025 [DOI] [PubMed] [Google Scholar]
- Wong S. K., Ma C. P., Foster D. C., Chen A. Y., Garbers D. L. (1995). The guanylyl cyclase-A receptor transduces an atrial natriuretic peptide/ATP activation signal in the absence of other proteins. J. Biol. Chem. 270 30818–30822 10.1074/jbc.270.51.30818 [DOI] [PubMed] [Google Scholar]
- Yang R. B., Foster D. C, Garbers D. L., Fulle H. J. (1995). Two membrane forms of guanylyl cyclase found in the eye. Proc. Natl. Acad. Sci. U.S.A. 92 602–606 10.1073/pnas.92.2.602 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhao D., Vellaichamy E., Somanna N. K., Pandey K. N. (2007). Guanylyl cyclase/natriuretic peptide receptor-A gene disruption causes increased adrenal angiotensin II and aldosterone levels. Am. J. Physiol. Renal Physiol. 293 F121–F127 10.1152/ajprenal.00478.2006 [DOI] [PubMed] [Google Scholar]
- Zozulya S., Stryer L. (1992). Calcium-myristoyl protein switch. Proc. Natl. Acad. Sci. U.S.A. 89 11569–11573 10.1073/pnas.89.23.11569 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zufall F., Munger S. D. (2010). Receptor guanylyl cyclases in mammalian olfactory function. Mol. Cell. Biochem. 334 191–197 10.1007/s11010-009-0325-9 [DOI] [PMC free article] [PubMed] [Google Scholar]